BACKGROUND AND PURPOSE: Ghrelin increases growth hormone secretion, gastric acid secretion, gastric motility and hunger but decreases glucose-dependent insulin secretion and insulin sensitivity in humans. Antagonizing the ghrelin receptor has potential as a therapeutic approach in the treatment of obesity and type 2 diabetes. Therefore, the aim was to pharmacologically characterize the novel small-molecule antagonist PF-05190457 and assess translational pharmacology ex vivo. EXPERIMENTAL APPROACH: Radioligand binding in filter and scintillation proximity assay formats were used to evaluate affinity, and europium-labelled GTP to assess functional activity. Rat vagal afferent firing and calcium imaging in dispersed islets were used as native tissues underlying food intake and insulin secretion respectively. KEY RESULTS: PF-05190457 was a potent and selective inverse agonist on constitutively active ghrelin receptors and acted as a competitive antagonist of ghrelin action, with a human Kd of 3 nM requiring 4 h to achieve equilibrium. Potency of PF-05190457 was similar across different species. PF-05190457 increased intracellular calcium within dispersed islets and increased vagal afferent firing in a concentration-dependent manner with similar potency but was threefold less potent as compared with the in vitro Ki in recombinant overexpressing cells. The effect of PF-05190457 on rodent islets was comparable with glibenclamide, but glucose-dependent and additive with the insulin secretagogue glucagon-like peptide-1. CONCLUSIONS AND IMPLICATIONS: Together, these data provide the pharmacological in vitro and ex vivo characterization of the first ghrelin receptor inverse agonist, which has advanced into clinical trials to evaluate the therapeutic potential of blocking ghrelin receptors in obesity and type 2 diabetes.
BACKGROUND AND PURPOSE:Ghrelin increases growth hormone secretion, gastric acid secretion, gastric motility and hunger but decreases glucose-dependent insulin secretion and insulin sensitivity in humans. Antagonizing the ghrelin receptor has potential as a therapeutic approach in the treatment of obesity and type 2 diabetes. Therefore, the aim was to pharmacologically characterize the novel small-molecule antagonist PF-05190457 and assess translational pharmacology ex vivo. EXPERIMENTAL APPROACH: Radioligand binding in filter and scintillation proximity assay formats were used to evaluate affinity, and europium-labelled GTP to assess functional activity. Rat vagal afferent firing and calcium imaging in dispersed islets were used as native tissues underlying food intake and insulin secretion respectively. KEY RESULTS:PF-05190457 was a potent and selective inverse agonist on constitutively active ghrelin receptors and acted as a competitive antagonist of ghrelin action, with a human Kd of 3 nM requiring 4 h to achieve equilibrium. Potency of PF-05190457 was similar across different species. PF-05190457 increased intracellular calcium within dispersed islets and increased vagal afferent firing in a concentration-dependent manner with similar potency but was threefold less potent as compared with the in vitro Ki in recombinant overexpressing cells. The effect of PF-05190457 on rodent islets was comparable with glibenclamide, but glucose-dependent and additive with the insulin secretagogue glucagon-like peptide-1. CONCLUSIONS AND IMPLICATIONS: Together, these data provide the pharmacological in vitro and ex vivo characterization of the first ghrelin receptor inverse agonist, which has advanced into clinical trials to evaluate the therapeutic potential of blocking ghrelin receptors in obesity and type 2 diabetes.
Authors: Svetozar S Damjanovic; Nebojsa M Lalic; Predrag M Pesko; Milan S Petakov; Aleksandra Jotic; Dragana Miljic; Katarina S Lalic; Ljiljana Lukic; Marina Djurovic; Vojko B Djukic Journal: J Clin Endocrinol Metab Date: 2006-04-18 Impact factor: 5.958
Authors: William P Esler; Joachim Rudolph; Thomas H Claus; Weifeng Tang; Nicole Barucci; Su-Ellen Brown; William Bullock; Michelle Daly; Lynn Decarr; Yaxin Li; Lucinda Milardo; David Molstad; Jian Zhu; Stephen J Gardell; James N Livingston; Laurel J Sweet Journal: Endocrinology Date: 2007-07-26 Impact factor: 4.736
Authors: Sharmilee Gnanapavan; Blerina Kola; Stephen A Bustin; Damian G Morris; Patrick McGee; Peter Fairclough; Satya Bhattacharya; Robert Carpenter; Ashley B Grossman; Márta Korbonits Journal: J Clin Endocrinol Metab Date: 2002-06 Impact factor: 5.958
Authors: F Broglio; C Gottero; F Prodam; C Gauna; G Muccioli; M Papotti; T Abribat; A J Van Der Lely; E Ghigo Journal: J Clin Endocrinol Metab Date: 2004-06 Impact factor: 5.958
Authors: Galina Burdyga; Andrea Varro; Rod Dimaline; David G Thompson; Graham J Dockray Journal: Am J Physiol Gastrointest Liver Physiol Date: 2006-01-19 Impact factor: 4.052
Authors: Mary R Lee; Mehdi Farokhnia; Enoch Cobbina; Anitha Saravanakumar; Xiaobai Li; Jillian T Battista; Lisa A Farinelli; Fatemeh Akhlaghi; Lorenzo Leggio Journal: Neuropharmacology Date: 2019-09-23 Impact factor: 5.250
Authors: William S Denney; Gabriele E Sonnenberg; Santos Carvajal-Gonzalez; Theresa Tuthill; V Margaret Jackson Journal: Br J Clin Pharmacol Date: 2016-10-29 Impact factor: 4.335
Authors: Grzegorz Godlewski; Resat Cinar; Nathan J Coffey; Jie Liu; Tony Jourdan; Bani Mukhopadhyay; Lee Chedester; Ziyi Liu; Douglas Osei-Hyiaman; Malliga R Iyer; Joshua K Park; Roy G Smith; Hiroshi Iwakura; George Kunos Journal: Cell Metab Date: 2019-05-16 Impact factor: 27.287
Authors: J Kong; J Chuddy; I A Stock; P M Loria; S V Straub; C Vage; K O Cameron; S K Bhattacharya; K Lapham; K F McClure; Y Zhang; V M Jackson Journal: Br J Pharmacol Date: 2016-03-17 Impact factor: 8.739